In a landmark shift for global HIV prevention strategies, the World Health Organization (WHO) has formally endorsed the use of lenacapavir, a long‑acting injectable medication administered only twice a year. This marks a potential turning point in efforts to combat HIV, offering a significantly more convenient and accessible option compared to daily oral pre‑exposure prophylaxis (PrEP). The recommendation was announced at the International AIDS Conference and positions lenacapavir as the most promising alternative to an HIV vaccine currently available.
Lenacapavir is a capsid inhibitor, meaning it disrupts the structure of the HIV viral core—preventing the virus from replicating in the human body. Clinical trials, notably the PURPOSE 1 and PURPOSE 2 studies, demonstrated nearly 100% effectiveness in preventing HIV infection among a wide range of participants—including cisgender women and gender‑diverse individuals—who used lenacapavir as a preventive measure. In comparison to daily oral PrEP, lenacapavir achieved significantly higher adherence rates and a stronger overall prevention outcome.
The WHO emphasized that lenacapavir greatly reduces the burden of strict daily medication regimens. For many users, especially those who face stigma or lack stable access to healthcare facilities, remembering and taking a pill every day can be a major barrier. With lenacapavir, two clinic visits annually provide full protection, alleviating the challenges of pill fatigue, supply interruptions, and privacy concerns.
This recommendation is particularly significant for key populations disproportionately affected by HIV. These include sex workers; men who have sex with men; transgender individuals; people who inject drugs; people in prison settings; and young women and adolescent girls in regions with high incidence rates. In many cases, these groups face structural challenges such as discrimination, limited access to healthcare services, and inconsistent access to medications. Lenacapavir’s bi‑annual delivery offers a more discreet, manageable option for individuals navigating complex social circumstances or unstable living conditions.
Historically, HIV prevention efforts have depended heavily on daily oral PrEP or long‑acting injectables like cabotegravir and the dapivirine vaginal ring. While these methods are effective, each has limitations: oral PrEP requires daily adherence, cabotegravir injections must be administered every two months, and the dapivirine ring must be replaced monthly. Lenacapavir simplifies this further by extending protection across six months per dose, streamlining both logistics and user experience. It broadens the prevention toolkit, enabling patients and healthcare providers to select the method best suited to individual lifestyle and risk profiles.
Despite its promise, the rollout of lenacapavir faces practical considerations. Ensuring affordability and equitable access—particularly in low- and middle-income countries—is critical. WHO and global health partners are working with governments, manufacturers, and drug licensing entities to accelerate regulatory approvals, facilitate generic manufacturing, and integrate lenacapavir into existing HIV prevention programs. This builds upon the precedent set by cabotegravir rollout, which paved the way for streamlined distribution and subsidy models in several regions.
Implementation challenges remain: lenacapavir requires a cold-chain infrastructure, proper training for healthcare workers to administer injections, and follow‑up protocols for side effects monitoring. Nonetheless, early implementation plans suggest these can be integrated efficiently into routine HIV services, especially in settings already supporting PrEP, antiretroviral therapy, or sexual health clinics.
Moving forward, WHO has called for further implementation research. Real‑world studies will monitor uptake, user retention, safety in diverse populations, and potential viral resistance patterns. While clinical trials showed minimal adverse effects, ongoing vigilance is essential, especially with long‑acting formulations. Tracking resistance will help ensure lenacapavir remains effective and that guidelines evolve in response to emerging data.
The significance of having an HIV prevention method requiring only two visits per year cannot be overstated. For individuals in rural areas, regions with limited transport options, or communities where attending clinics prompts social scrutiny, lenacapavir could remove major barriers. Convenience and discretion may translate into higher overall participation in prevention programs, reducing new HIV infections at scale.
Moreover, lenacapavir can support integrated delivery models—for example, synchronized with immunization programs, maternal health check-ups, or general outpatient visits. In settings where people already visit clinics periodically, lenacapavir could be administered seamlessly without additional logistic strain, boosting coverage while maintaining healthcare efficiency.
While lenacapavir does not replace existing PrEP options, it complements them. Some users may prefer oral PrEP for flexibility, while others favor the dapivirine ring or cabotegravir depending on their anatomy, risk profile, and personal preference. Lenacapavir now enriches this menu, offering a rare choice: the convenience of long‑acting protection with minimal intervention.
Lenacapavir’s potential impact on public health is profound. With approximately 1.3 million new HIV infections occurring globally in 2024, prevention efforts have plateaued. Key demographic groups continue to bear the brunt of new transmissions. A tool like lenacapavir—if made widely accessible—could break through stagnation by increasing adoption in underserved and high-risk communities.
Critics caution that new interventions—especially injectables—can carry risks. Injection site reactions and potential long-term side effects must be monitored carefully. Additionally, concerns about emerging drug resistance, should HIV mutate in response to lenacapavir pressure, underscore the need for robust surveillance programs. WHO’s recommendation therefore includes caveats for post‑implementation monitoring and combination strategies (e.g. adherence counseling, regular HIV testing, and access to alternative prevention methods).
Despite these considerations, the benefits appear to outweigh the challenges. For public health officials, lenacapavir offers a powerful new lever to reduce transmission, especially in regions with persistent barriers to daily medication use.
Ultimately, WHO’s endorsement of lenacapavir is more than a policy update—it’s a leap forward in reimagining HIV prevention. It recognizes not only biomedical advances but also the realities of social, cultural, and structural barriers faced by vulnerable individuals worldwide. As global health systems adopt this twice‑yearly injectable regimen, communities previously unable or unwilling to engage with daily PrEP may now find a viable, effective alternative.
If momentum continues, lenacapavir could transform prevention landscapes—lowering new infections, enhancing user choice, and bringing us closer to long-term epidemic control goals. The trajectory now depends on how swiftly health systems can integrate this innovation with equity and sustainability in mind. In the fight against HIV, lenacapavir may well become a defining tool—offering protection, dignity, and hope with only two injections per year.